Pharmacy & Therapeutics - December 2008 - (Page 730)

CONTINUING EDUCATION CREDIT Continuing Education Questions for Physicians and Pharmacists TOPIC: Classification and Pharmacological Management of Obesity ACPE Program # 079-000-08-024-H01-P CE Evaluation: Select the one best answer to each of the following questions, and record your response on the examination answer sheet. Complete the additional requested information. Forward the answer sheet, with appropriate payment, to the Department of Health Policy, Thomas Jefferson University Hospital, at the address indicated. A certificate of completion will be mailed within six to eight weeks of receipt of your exam/payment. (A minimum test score of 70% is required.) Multiple Choice Select the one correct answer. 1. According to this article, a patient should be assessed for obesity by: a. calculating body mass index (BMI) and measuring waist circumference. b. directly measuring body fat. c. measuring the waist-to-hip ratio. d. simply weighing the patient. As stated in the article, what should the initial weight loss goal be for an obese patient? a. a 1% to 5% reduction from baseline weight b. a 5% to 10% reduction from baseline weight c. a 10% to 15% reduction from baseline weight d. a 15% to 20% reduction from baseline weight According to the authors, which of the following should be present before a patient is eligible for bariatric surgery? a. BMI ≥ 30 kg/m2 and a comorbidity such as diabetes or joint disease b. BMI ≥ 30 kg/m2 c. BMI ≥ 40 kg/m2 and a comorbidity such as diabetes or joint disease d. BMI ≥ 40 kg/m2 Which of the following is the least invasive of the bariatric surgeries? a. duodenal switch b. laparoscopic adjustable band c. Roux-en-Y gastric bypass d. vertical banded gastroplasty According to the article, phentermine (Adipex-P, Ionamin) is most structurally similar to: a. phenelzine. b. fenfluramine. c. dextroamphetamine. d. diphenhydramine. 6. Therapy with phentermine should be discontinued if significant weight loss is not observed after how many weeks? a. 1 to 2 weeks b. 4 to 6 weeks c. 1 to 12 weeks d. 22 to 24 weeks Risks associated with sibutramine include all of the following except: a. increased blood pressure. b. increased heart rate. c. decreased serotonergic activity in the central nervous system. d. constipation. Orlistat works via which mechanism of action? a. as a cannabinoid-1 receptor antagonist b. stimulation of the hypothalamus c. blocking of neuronal uptake of norepinephrine, serotonin, and dopamine d. inhibition of gastrointestinal lipases Rimonabant has not been approved for use in the U.S. because of the medication’s a. effect on blood pressure. b. psychiatric side effects. c. gastrointestinal side effects. d. numerous drug interactions. 2. 7. 3. 8. 9. 4. 5. 10. Tesofensine, a novel agent in phase 2 trials, is an uptake inhibitor of which neurotransmitters? a. serotonin and dopamine b. dopamine and noradrenaline c. noradrenaline and serotonin d. serotonin, noradrenaline, and dopamine 730 P&T® • December 2008 • Vol. 33 No. 12

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - December 2008

Pharmacy & Therapeutics - December 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/ New Medical Devices Drug Forecast Interpreting Estimates of Treatment Effects Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow Third Annual Onmark National Payor/Provider Forum Fourth Annual Ophthalmic Drug Development and Delivery Summit Classification and Pharmacological Management Of Obesity CE Test and Forms Season’s Greetings: Thanks to Our Readers and Reviewers

Pharmacy & Therapeutics - December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.